AGMB (AgomAb Therapeutics NV) Shares Outstanding (EOP): 48.74 Mil (As of Dec. 2025)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Shares Outstanding (EOP)?

AgomAb Therapeutics NV AGMB +0.85% 14 Shares Outstanding (EOP) is 48.74 Mil as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. AgomAb Therapeutics NV's shares outstanding for the quarter that ended in Dec. 2025 was 48.74 Mil.

AgomAb Therapeutics NV's quarterly shares outstanding stayed the same from Sep. 2025 (48.74 Mil) to Dec. 2025 (48.74 Mil).

AgomAb Therapeutics NV's annual shares outstanding stayed the same from Dec. 2024 (48.74 Mil) to Dec. 2025 (48.74 Mil).


AgomAb Therapeutics NV  (NAS:AGMB) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


AgomAb Therapeutics NV Shares Outstanding (EOP) Related Terms


AgomAb Therapeutics NV Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Shares Outstanding (EOP) Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
0.00 48.74 48.74 48.74 48.74

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial 48.74 48.74 48.74 48.74 48.74

AGMB vs DNA, ACRS, RLMD: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, AgomAb Therapeutics NV's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AgomAb Therapeutics NV Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AgomAb Therapeutics NV's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where AgomAb Therapeutics NV's Shares Outstanding (EOP) falls into.


AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 48.74 Mil mean?
AgomAb Therapeutics NV (AGMB) has a Shares Outstanding (EOP) of 48.74 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on AgomAb Therapeutics NV and its competitors.
Is AgomAb Therapeutics NV's Shares Outstanding (EOP) too high?
AgomAb Therapeutics NV's current Shares Outstanding (EOP) is 48.74 Mil. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Shares Outstanding (EOP) compare to DNA and ACRS?
AgomAb Therapeutics NV's Shares Outstanding (EOP) of 48.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Shares Outstanding (EOP) is 48.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Shares Outstanding (EOP) of 48.74 Mil. The current Shares Outstanding (EOP) is 48.74 Mil. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Shares Outstanding (EOP) is 48.74 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price